Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update March 31, 2025 4:00 PM EDT | Source: Phio Pharmaceuticals Corp. Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-762 3rd Cohort now fully enrolled in on-going clinical study Marlborough, Massachusetts--(Newsfile Corp. - March 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing te ...

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual MeetingInterim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarch 10, 2025 7:45 AM EDT | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene si ...

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation StudyMarch 05, 2025 7:45 AM EST | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio annou ...

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of DirectorsFebruary 20, 2025 7:45 AM EST | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of ...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesRegistration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm ESTFebruary 03, 2025 7:45 AM EST | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - February 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silenc ...

Clinical Trial Results - Phio Pharmaceuticals reported pathologic complete response (100% tumor clearance) in 2 patients with cutaneous squamous cell carcinoma (cSCC) from the second cohort of its ongoing Phase 1b clinical study [1] - In the second cohort, 1 patient with cSCC showed a partial response (90% tumor clearance) and 1 patient had stable disease without progression [8] - No dose-limiting toxicities or clinically relevant treatment-emergent adverse events were observed in patients receiving intratumoral PH-762, indicating good tolerability [8] PH-762 and INTASYL Technology - PH-762 is an INTASYL compound designed to silence PD-1, potentially offering a non-surgical treatment for skin cancers [9] - INTASYL siRNA gene silencing technology enhances the ability of immune cells to kill tumor cells and has demonstrated efficacy in adoptive cell therapy [6] - The technology targets and silences genes with high specificity across various cell types and tissues without requiring formulation enhancements [6] Study Design and Progress - The ongoing Phase 1b clinical study (NCT 06014086) evaluates the safety and tolerability of neoadjuvant intratumoral PH-762 in patients with Stages 1, 2, and 4 cSCC, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma [5] - The study has enrolled 6 patients with cSCC and 1 patient with metastatic melanoma to date [8] - The company plans to continue enrollment to assess higher dose concentrations of PH-762 [2] Strategic Vision and Leadership Commentary - The company's vision is to strive for a cancer-free future using INTASYL technology, as stated by CEO Robert Bitterman [2] - Mary Spellman, Phio's acting Chief Medical Officer, expressed encouragement over the profound tumor response and reassuring safety data from the second cohort [2]

Phio Pharmaceuticals Announces Publication in Frontiers in ImmunologyJournal is the official publication of the International Union of Immunological SocietiesDecember 12, 2024 9:21 AM EST | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - December 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more ...

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical StudyNovember 19, 2024 7:45 AM EST | Source: Phio Pharmaceuticals Corp.--Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring new pathways towards a cancer-free future, today announced it has completed the enrollment of its ...

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 14, 2024 5:47 PM EST | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36304 Phio Pharmaceuticals Corp. (Exact name of registrant as specified in its charter) Delaware 45-3215903 (State o ...